These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

913 related articles for article (PubMed ID: 17895320)

  • 1. RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center.
    Elisei R; Romei C; Cosci B; Agate L; Bottici V; Molinaro E; Sculli M; Miccoli P; Basolo F; Grasso L; Pacini F; Pinchera A
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4725-9. PubMed ID: 17895320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Twenty years of lesson learning: how does the RET genetic screening test impact the clinical management of medullary thyroid cancer?
    Romei C; Tacito A; Molinaro E; Agate L; Bottici V; Viola D; Matrone A; Biagini A; Casella F; Ciampi R; Materazzi G; Miccoli P; Torregrossa L; Ugolini C; Basolo F; Vitti P; Elisei R
    Clin Endocrinol (Oxf); 2015 Jun; 82(6):892-9. PubMed ID: 25440022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical utility of genetic diagnosis for sporadic and hereditary medullary thyroid carcinoma.
    Elisei R; Bottici V; Cappagli V; Ramone T; Tacito A; Ciampi R; Romei C
    Ann Endocrinol (Paris); 2019 Jun; 80(3):187-190. PubMed ID: 31053251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
    Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece.
    Sarika HL; Papathoma A; Garofalaki M; Vasileiou V; Vlassopoulou B; Anastasiou E; Alevizaki M
    Clin Endocrinol (Oxf); 2012 Dec; 77(6):857-62. PubMed ID: 22676047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto-oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal.
    Prazeres HJ; Rodrigues F; Figueiredo P; Naidenov P; Soares P; Bugalho MJ; Lacerda M; Campos B; Martins TC
    Clin Endocrinol (Oxf); 2006 Jun; 64(6):659-66. PubMed ID: 16712668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in the spectrum of RET mutations diagnosed between 1994 and 2006.
    Frank-Raue K; Rondot S; Schulze E; Raue F
    Clin Lab; 2007; 53(5-6):273-82. PubMed ID: 17605401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RET proto-oncogene mutations in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma.
    Marsh DJ; Mulligan LM; Eng C
    Horm Res; 1997; 47(4-6):168-78. PubMed ID: 9167949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutational spectrum of multiple endocrine neoplasia type 2 and sporadic medullary thyroid carcinoma in taiwan.
    Chang CF; Yang WS; Su YN; Wu IL; Chang TC
    J Formos Med Assoc; 2009 May; 108(5):402-8. PubMed ID: 19443294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
    Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
    Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
    Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular analysis of the RET proto-oncogene key exons in patients with medullary thyroid carcinoma: a comprehensive study of the Iranian population.
    Alvandi E; Akrami SM; Chiani M; Hedayati M; Nayer BN; Tehrani MR; Nakhjavani M; Pedram M
    Thyroid; 2011 Apr; 21(4):373-82. PubMed ID: 21309721
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinction between sporadic and hereditary medullary thyroid carcinoma (MTC) by mutation analysis of the RET proto-oncogene. "Study Group Multiple Endocrine Neoplasia Austria (SMENA)".
    Fink M; Weinhüsel A; Niederle B; Haas OA
    Int J Cancer; 1996 Aug; 69(4):312-6. PubMed ID: 8797874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Germline mutations of the ret proto-oncogene in Chilean patients with hereditary and sporadic medullary thyroid carcinoma].
    Wohllk N; Becker P; Youlton R; Cote GJ; Gagel RF
    Rev Med Chil; 2001 Jul; 129(7):713-8. PubMed ID: 11552438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A large family with hereditary MTC: role of RET genetic analysis in differential diagnosis between MEN 2A and FMTC.
    Chiefari E; Chiarella R; Crocetti U; Tardio B; Arturi F; Russo D; Trischitta V; Filetti S; Zingrillo M
    Horm Metab Res; 2001 Jan; 33(1):52-6. PubMed ID: 11280716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
    Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic.
    Jindrichová S; Vcelák J; Vlcek P; Neradilová M; Nemec J; Bendlová B
    J Endocrinol; 2004 Nov; 183(2):257-65. PubMed ID: 15531714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RET proto-oncogene mutations are restricted to codon 634 and 618 in Korean families with multiple endocrine neoplasia 2A.
    Chung YJ; Kim HH; Kim HJ; Min YK; Lee MS; Lee MK; Kim KW; Ki CS; Kim JW; Chung JH
    Thyroid; 2004 Oct; 14(10):813-8. PubMed ID: 15588376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.
    Romei C; Mariotti S; Fugazzola L; Taccaliti A; Pacini F; Opocher G; Mian C; Castellano M; degli Uberti E; Ceccherini I; Cremonini N; Seregni E; Orlandi F; Ferolla P; Puxeddu E; Giorgino F; Colao A; Loli P; Bondi F; Cosci B; Bottici V; Cappai A; Pinna G; Persani L; Verga U; Boscaro M; Castagna MG; Cappelli C; Zatelli MC; Faggiano A; Francia G; Brandi ML; Falchetti A; Pinchera A; Elisei R;
    Eur J Endocrinol; 2010 Aug; 163(2):301-8. PubMed ID: 20516206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RET genetic screening in patients with medullary thyroid cancer: the Moroccan experience.
    Abdelhakim A; Barlier A; Kebbou M; Benabdeljalil N; Timinouni M; Taoufiq F; Roche C; El Antri S
    J Cancer Res Ther; 2009; 5(3):198-202. PubMed ID: 19841562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 46.